Role of dietary fats in modulating cardiometabolic risk during moderate weight gain: A randomized double-blind overfeeding trial (LIPOGAIN Study)

Journal of the American Heart Association

Volumn 3, Issue 5, 2014, Pages

  Iggman, David ^a,c   Rosqvist, Fredrik ^a   Larsson, Anders ^b   Ärnlöv, Johan ^b,d   Beckman, Lena ^e,f   Rudling, Mats ^e,f   Risérus, Ulf ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c Dalarna   (Sweden)

^d DALARNA UNIVERSITY   (Sweden)

^e Departments of Medicine and Biosciences and Nutrition   (Sweden)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Atherosclerosis; Lipids; Lipoprotein; Nutrition; Obesity

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBROBLAST GROWTH FACTOR 21; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PALM OIL; POLYUNSATURATED FATTY ACID; PROINSULIN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SATURATED FATTY ACID; SERINE PROTEINASE; SUNFLOWER OIL; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; CHOLESTEROL; FAT INTAKE; GLUCOSE BLOOD LEVEL; LIPID; LIPOPROTEIN; VEGETABLE OIL;

ADULT; ARTICLE; CALORIC INTAKE; CARDIOMETABOLIC RISK; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; NORMAL HUMAN; OVERNUTRITION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; WEIGHT GAIN; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; ANALYSIS; ATHEROSCLEROSIS; BLOOD; BLOOD ANALYSIS; BODY WEIGHT; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; DIET THERAPY; FAT INTAKE; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; OBESITY; PATHOPHYSIOLOGY; SWEDEN; YOUNG ADULT;

ADULT; ATHEROSCLEROSIS; BLOOD CHEMICAL ANALYSIS; BLOOD GLUCOSE; BODY WEIGHT; CARDIOVASCULAR DISEASES; CHOLESTEROL; DIET, HIGH-FAT; DIETARY FATS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INSULIN RESISTANCE; LIPIDS; LIPOPROTEINS; MALE; OBESITY; PLANT OILS; RISK ASSESSMENT; SWEDEN; WEIGHT GAIN; YOUNG ADULT;

EID: 84922883500     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.001095     Document Type: Article

References (41)

1. Estruch R, Ros E, Salas-Salvadó J, Covas M-I, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez-González MA. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279-1290.
2. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003;77:1146-1155.
3. Sanders TA. Fat and fatty acid intake and metabolic effects in the human body. Ann Nutr Metab. 2009;55:162-172.
4. Astrup A, Dyerberg J, Elwood P, Hermansen K, Hu FB, Jakobsen MU, Kok FJ, Krauss RM, Lecerf JM, Legrand P, Nestel P, Riserus U, Sanders T, Sinclair A, Stender S, Tholstrup T, Willett W. The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010? Am J Clin Nutr. 2011;93:684-688.
5. Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2010;7: e1000252.
6. Rosqvist F, Iggman D, Kullberg J, Cedernaes J, Johansson HE, Larsson A, Johansson L, Ahlstrom H, Arner P, Dahlman I, Riserus U. Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans. Diabetes. 2014;63:2356-2368.
7. Kempen HJ, Glatz JF, Gevers Leuven JA, van der Voort HA, Katan MB. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res. 1988;29:1149-1155.
8. Bjermo H, Iggman D, Kullberg J, Dahlman I, Johansson L, Persson L, Berglund J, Pulkki K, Basu S, Uusitupa M, Rudling M, Arner P, Cederholm T, Ahlstrom H, Riserus U. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am J Clin Nutr. 2012;95:1003-1012.
9. Boberg M, Vessby B, Croon LB. Fatty acid composition of platelets and of plasma lipid esters in relation to platelet function in patients with ischaemic heart disease. Atherosclerosis. 1985;58:49-63.
10. Sanders TA, Lewis FJ, Goff LM, Chowienczyk PJ. SFAs do not impair endothelial function and arterial stiffness. Am J Clin Nutr. 2013;98:677-683.
11. Lin J, Yang R, Tarr PT, Wu PH, Handschin C, Li S, Yang W, Pei L, Uldry M, Tontonoz P, Newgard CB, Spiegelman BM. Hyperlipidemic effects of dietary saturated fats mediated through pgc-1beta coactivation of srebp. Cell. 2005;120:261-273.
12. Jump DB, Botolin D, Wang Y, Xu J, Christian B, Demeure O. Fatty acid regulation of hepatic gene transcription. J Nutr. 2005;135:2503-2506.
13. Hannah VC, Ou J, Luong A, Goldstein JL, Brown MS. Unsaturated fatty acids down-regulate srebp isoforms 1a and 1c by two mechanisms in HEK-293 cells. J Biol Chem. 2001;276:4365-4372.
14. Orr JS, Gentile CL, Davy BM, Davy KP. Large artery stiffening with weight gain in humans: role of visceral fat accumulation. Hypertension. 2008;51:1519-1524.
15. Erlingsson S, Herard S, Dahlqvist Leinhard O, Lindstrom T, Lanne T, Borga M, Nystrom FH; Fast Food Study G. Men develop more intraabdominal obesity and signs of the metabolic syndrome after hyperalimentation than women. Metabolism. 2009;58:995-1001.
16. Oppert JM, Nadeau A, Tremblay A, Despres JP, Theriault G, Deriaz O, Bouchard C. Plasma glucose, insulin, and glucagon before and after long-term overfeeding in identical twins. Metabolism. 1995;44:96-105.
17. Brands M, Swat M, Lammers NM, Sauerwein HP, Endert E, Ackermans MT, Verhoeven AJ, Serlie MJ. Effects of a hypercaloric diet on beta-cell responsivity in lean healthy men. Clin Endocrinol. 2013;78:217-225.
18. Erdmann J, Kallabis B, Oppel U, Sypchenko O, Wagenpfeil S, Schusdziarra V. Development of hyperinsulinemia and insulin resistance during the early stage of weight gain. Am J Physiol Endocrinol Metab. 2008;294:E568-E575.
19. Gupta AK, Johnson WD, Johannsen D, Ravussin E. Cardiovascular risk escalation with caloric excess: a prospective demonstration of the mechanics in healthy adults. Cardiovasc Diabetol. 2013;12:23.
20. Samocha-Bonet D, Campbell LV, Mori TA, Croft KD, Greenfield JR, Turner N, Heilbronn LK. Overfeeding reduces insulin sensitivity and increases oxidative stress, without altering markers of mitochondrial content and function in humans. PLoS One. 2012;7:e36320.
21. Tam CS, Viardot A, Clement K, Tordjman J, Tonks K, Greenfield JR, Campbell LV, Samocha-Bonet D, Heilbronn LK. Short-term overfeeding may induce peripheral insulin resistance without altering subcutaneous adipose tissue macrophages in humans. Diabetes. 2010;59:2164-2170.
22. Astrand O, Carlsson M, Nilsson I, Lindstrom T, Borga M, Nystrom FH; Fast Food Study G. Weight gain by hyperalimentation elevates C-reactive protein levels but does not affect circulating levels of adiponectin or resistin in healthy subjects. Eur J Endocrinol. 2010;163:879-885.
23. Zethelius B, Byberg L, Hales CN, Lithell H, Berne C. Proinsulin is an independent predictor of coronary heart disease: report from a 27-year follow-up study. Circulation. 2002;105:2153-2158.
24. Lindstrom T, Kechagias S, Carlsson M, Nystrom FH; Fast Food Study G. Transient increase in HDL-cholesterol during weight gain by hyperalimentation in healthy subjects. Obesity (Silver Spring). 2011;19:812-817.
25. Investigators A-H, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-2267.
26. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Holm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PI, Klungel OH, Maitland-van der Zee AH, Peters BJ, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WM, Boer JM, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, Konig IR, Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, Van de Werf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Schafer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, O'Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572-580.
27. Meugnier E, Bossu C, Oliel M, Jeanne S, Michaut A, Sothier M, Brozek J, Rome S, Laville M, Vidal H. Changes in gene expression in skeletal muscle in response to fat overfeeding in lean men. Obesity (Silver Spring). 2007;15:2583-2594.
28. Park SW, Moon YA, Horton JD. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem. 2004;279:50630-50638.
29. Vienberg SG, Brons C, Nilsson E, Astrup A, Vaag A, Andersen B. Impact of short-term high-fat feeding and insulin-stimulated FGF21 levels in subjects with low birth weight and controls. Eur J Endocrinol. 2012;167:49-57.
30. Woo YC, Xu A, Wang Y, Lam KS. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol. 2013;78:489-496.
31. Iggman D, Gustafsson IB, Berglund L, Vessby B, Marckmann P, Riserus U. Replacing dairy fat with rapeseed oil causes rapid improvement of hyperlipidaemia: a randomized controlled study. J Intern Med. 2011;270:356-364.
32. Stegemann C, Pechlaner R, Willeit P, Langley SR, Mangino M, Mayr U, Menni C, Moayyeri A, Santer P, Rungger G, Spector TD, Willeit J, Kiechl S, Mayr M. Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. Circulation. 2014;129:1821-1831.
33. Mozaffarian D, Appel LJ, Van Horn L. Components of a cardioprotective diet: new insights. Circulation. 2011;123:2870-2891.
34. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, Lee IM, Lichtenstein AH, Loria CM, Millen BE, Nonas CA, Sacks FM, Smith SC Jr, Svetkey LP, Wadden TA, Yanovski SZ, Kendall KA, Morgan LC, Trisolini MG, Velasco G, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S76-S99.
35. Prospective Studies C, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829-1839.
36. Lamarche B, Despres JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ. Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease: results from the Quebec cardiovascular study. Atherosclerosis. 1996;119:235-245.
37. van Lennep JE, Westerveld HT, van Lennep HW, Zwinderman AH, Erkelens DW, van der Wall EE. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol. 2000;20:2408-2413.
38. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026-2033.
39. Chien KL, Hsu HC, Su TC, Chen MF, Lee YT, Hu FB. Apolipoprotein B and nonhigh density lipoprotein cholesterol and the risk of coronary heart disease in Chinese. J Lipid Res. 2007;48:2499-2505.
40. Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendorfer A, Beere PA, Watson DJ, Downs JR, de Cani JS. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477-484.
41. Sacks FM. The apolipoprotein story. Atheroscler Suppl. 2006;7:23-27.